

Vaccine process. Conjugated polysaccharide. Products. Services. Expertise.

The global conjugated polysaccharide vaccine market is expected to experience continued expansion with the new requirements in emerging countries, such as higher number of doses; changing national immunization programs in developed countries; and the inclusion of many conjugated polysaccharide vaccines in the WHO priority lists.


From a manufacturing perspective, vaccines manufacturers are concerned with balancing speed to market and cost containment, while maintaining product safety. This implies many process challenges such as:

- increasing process efficiency and product recovery
- achieving higher product yield
- ensuring process safety and reproducibility of multi-strain products

Merck Millipore's regulatory know-how, integrated portfolio, and applications expertise can help you overcome your vaccines process challenges.

No guide will replace the need to conduct process development and optimization experiments. The unique nature of every process stream combined with application and regulatory requirements play a part in determining the optimum process solutions. Use this selection guide as a starting point for selecting and sizing the most appropriate Merck Millipore solutions.

Vaccines process. Conjugated polysaccharide. Products. Services. Expertise.



We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The holder of the manufacturing authorization shall ensure that the excipients are suitable for use in medicinal products by ascertaining the appropriate good manufacturing practice.

This is particularly true if the material in a certain application is regarded as high risk excipient, for example in parenteral dosage forms.

To place an order or receive technical assistance

In Europe, please call Customer Service:

France: 0825 045 645

Germany: 01805 045 645

Italy: 848 845 645

Spain: 901 516 645 Option 1

Switzerland: 0848 645 645

United Kingdom: 0870 900 4645

For other countries across Europe,
please call: +44 (0) 115 943 0840

Or visit www.merckmillipore.com/offices

For Technical Service visit: www.merckmillipore.com/techservice



www.merckmillipore.com

¹ based on IPEC - PQG GMP guide for pharmaceutical excipients 2006.

Merck Millipore, the M mark, and Polysep are trademarks of Merck KGaA, Darmstadt, Germany. Aervent, Biomax, Cogent, Durapore, Eshmuno, EMPROVE, EMSURE, Flexware, Fractogel, IsoPak, Integritest, K-Prime, Lynx, Millipore Express, Millistak+, Mobius, Pellicon, Provantage, Polygard, QuikScale, and Ultracel are registered trademarks of Merck KGaA, Darmstadt, Germany. NovAseptic, and NovaSeptum are registered trademarks of Millipore AB. Lit No: PS4420EN00 Rev. B. © 2014 EMD Millipore Corporation, Billerica, MA, USA. All rights reserved.